The Patent Finder

Mdxhealth S.A.

14 patents currently held · Updated Nov 18, 2026
7 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

7
Ending by 2030
Sep 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Dec 9 to 25, 2026 · next Dec 9
  • 1 fee due Mar 26, 2027
    The maintenance fee for Method for Predicting and Treating Clinically Significant Prostate Cancer (US 11,767,563) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
  • 1 fee due Oct 26, 2027
    The maintenance fee for Methods for Determining Methylation of the TWIST1 Gene for Bladder Cancer Detection (US 9,322,065) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,113,202Method for Determining the Methylation Status of the Promoter Region of the TWIST1 Gene in Genomic DNA from Bladder Cells
In force
 · High confidence
In forceHigh confidence
US 10,053,724Methylation Detection of the MGMT Promoter
In force
 · High confidence
In forceHigh confidence
US 9,371,569Detection and Prognosis of Cervical Cancer
In force
 · Medium confidence
In forceMedium confidence
US 10,041,128Methylation of the EPB41L3 Gene or the Promoter of the EPB41L3 Gene in a Test Sample Comprising Cervical Cells
In force
 · Medium confidence
In forceMedium confidence
US 9,322,065Methods for Determining Methylation of the TWIST1 Gene for Bladder Cancer Detection
In force
 · High confidence
In forceHigh confidence
US 9,388,471Methylation of the GATA4 Gene in Urine Samples as a Marker for Bladder Cancer Detection
In force
 · High confidence
In forceHigh confidence
US 9,050,280Methylation Detection of MGMT
In force
 · High confidence
In forceHigh confidence
US 10,260,104Method for Using Gene Expression to Determine Prognosis of Prostate Cancer
In force
 · High confidence
In forceHigh confidence
US 9,605,312Methods of Detecting Mutations in Braf and Epigenetic Changes
In force
 · High confidence
In forceHigh confidence
US 8,725,426Gene Expression Profile Algorithm and Test for Determining Prognosis of Prostate Cancer
In force
 · High confidence
In forceHigh confidence
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
Also on record, not counted in the 14: 7 patents in force now held by others · 1 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 7 abandoned · 1 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited